UNSPSC 51102851: Gramicidin/neomycin/nystatin/triamcinolone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102851 Gramicidin/neomycin/nystatin/triamcinolone is a Commodity code that in recent state and local procurement does not align with its nominal pharmaceutical ingredient scope. The three most recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription program design, generic multi-source pharmaceutical and OTC supply contracts, and emergency medical and first aid supplies — none of which are gramicidin/neomycin/nystatin/triamcinolone formulations. The code shows little relevant recent activity for its specified antibiotic-antifungal-corticosteroid combination product; solicitations under the code number address broader pharmaceutical distribution and emergency medical supply categories that fall outside the narrow ingredient-specific scope. State and local issuers tagging opportunities under this code appear to be using it as a catch-all for pharmaceutical and medical supply procurement rather than targeting a specific finished-goods product line.

The recent opportunities span Florida (Seminole County's naloxone and drug deactivation systems procurement, IFB due July 26, 2023), Texas (Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions, response deadline April 3, 2026), Florida (City of Tampa Fire Department medical and first aid supplies IFB, due March 13, 2026, with $700,000 estimated contract value and an SLBE set-aside), and Minnesota (MMCAP generic multi-source pharmaceuticals and OTC products RFP, due March 26, 2026, spanning Minnesota and Oregon through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). The issuing-body mix includes county health departments, state health agencies, municipalities, and regional cooperative purchasing alliances. This code warrants close scrutiny by vendors targeting gramicidin/neomycin/nystatin/triamcinolone — the recent procurement activity does not reflect demand for that specific product and suggests either miscoding by state and local procurement offices or a mismatch between the code's intended scope and current procurement practice.